Rigel Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Rigel Pharmaceuticals de 43.3% y 13% por año respectivamente. Se prevé que el BPA crezca en un 41.8% al año. Se espera que la rentabilidad financiera sea de 136.5% en 3 años.

Información clave

43.3%

Tasa de crecimiento de los beneficios

41.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.5%
Tasa de crecimiento de los ingresos	13.0%
Rentabilidad financiera futura	136.5%
Cobertura de analistas	Good
Última actualización	13 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Nov 08

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 10

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Sep 25

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Jul 30

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:RIGL - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	226	38	39	N/A	6
12/31/2025	194	20	6	N/A	6
12/31/2024	169	9	N/A	N/A	6
9/30/2024	157	4	10	11	N/A
6/30/2024	130	-14	-13	-12	N/A
3/31/2024	119	-20	-7	-7	N/A
12/31/2023	116	-25	-21	-6	N/A
9/30/2023	129	-24	-36	-21	N/A
6/30/2023	121	-38	-49	-33	N/A
3/31/2023	125	-45	-67	-52	N/A
12/31/2022	116	-59	-74	-74	N/A
9/30/2022	86	-83	-71	-71	N/A
6/30/2022	87	-85	-68	-68	N/A
3/31/2022	77	-85	-1	0	N/A
12/31/2021	139	-18	5	6	N/A
9/30/2021	138	-15	8	9	N/A
6/30/2021	136	-8	-1	0	N/A
3/31/2021	131	-11	-70	-69	N/A
12/31/2020	109	-30	-53	-52	N/A
9/30/2020	106	-28	-48	-46	N/A
6/30/2020	108	-25	-43	-41	N/A
3/31/2020	102	-28	-46	-44	N/A
12/31/2019	59	-67	-43	-42	N/A
9/30/2019	82	-46	-21	-20	N/A
6/30/2019	66	-59	-26	-26	N/A
3/31/2019	57	-64	-37	-36	N/A
12/31/2018	45	-70	-60	-59	N/A
9/30/2018	7	-100	-91	-90	N/A
6/30/2018	3	-93	N/A	-88	N/A
3/31/2018	1	-87	N/A	-80	N/A
12/31/2017	4	-78	N/A	-78	N/A
9/30/2017	7	-68	N/A	-70	N/A
6/30/2017	10	-73	N/A	-75	N/A
3/31/2017	19	-67	N/A	-74	N/A
12/31/2016	20	-69	N/A	-76	N/A
9/30/2016	26	-66	N/A	-77	N/A
6/30/2016	35	-50	N/A	-64	N/A
3/31/2016	32	-51	N/A	-64	N/A
12/31/2015	29	-51	N/A	-23	N/A
9/30/2015	29	-61	N/A	-25	N/A
6/30/2015	16	-75	N/A	-34	N/A
3/31/2015	10	-87	N/A	-35	N/A
12/31/2014	8	-91	N/A	-70	N/A
9/30/2014	6	-85	N/A	-74	N/A
6/30/2014	6	-88	N/A	-76	N/A
3/31/2014	7	-86	N/A	-77	N/A
12/31/2013	7	-89	N/A	-86	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (43.3% al año) de RIGL es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (43.3% al año) de RIGL crezcan más rápidamente que el mercado US (15.4% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de RIGL crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (13% al año) de RIGL crezcan más rápidamente que los del mercado US (8.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 13% al año) de RIGL crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de RIGL sea muy elevada dentro de 3 años (136.5%).

Rigel Pharmaceuticals Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 7.2% to US$28.67

Price target increased by 34% to US$26.75

Forecast breakeven date moved forward to 2024

Consensus EPS estimates upgraded to US$0.43 loss

Price target increased by 44% to US$65.33

Consensus EPS estimates upgraded to US$0.65 loss

Recent updates

Price target increased by 7.2% to US$28.67

Now 68% overvalued after recent price rise

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Rigel Pharmaceuticals, Inc. Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML

Price target increased by 34% to US$26.75

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2024

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Rigel Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Consensus EPS estimates upgraded to US$0.43 loss

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Price target increased by 44% to US$65.33

Consensus EPS estimates upgraded to US$0.65 loss

Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application

Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress

Insufficient new directors

Consensus EPS estimates upgraded to US$0.062 loss

Consensus EPS estimates upgraded to US$0.073 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target increased by 14% to US$5.08

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Consensus EPS estimates fall by 13%

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

Consensus estimates of losses per share improve by 12%

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date moved forward to 2025

Price target increased by 10% to US$4.46

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

President recently sold US$60k worth of stock

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

No longer forecast to breakeven

New minor risk - Share price stability

Forecast to breakeven in 2025

Rigel Pharmaceuticals, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Consensus EPS estimates upgraded to US$0.19 loss

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial

Consensus EPS estimates upgraded to US$0.25 loss

New minor risk - Profitability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Price target increased by 7.6% to US$3.85

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023

Rigel Pharmaceuticals, Inc. Announces Publication of REZLIDHIA (Olutasidenib) Phase 2 Clinical Results in Blood Advances

National Comprehensive Cancer Network Adds Newly Approved Rigel Pharmaceuticals, Inc.'s REZLIDHIA™ (Olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

Price target increased to US$4.11

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Rigel Pharmaceuticals, Inc. Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals, Inc. Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

Rigel Pharmaceuticals, Inc. Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals Received a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Rigel Pharmaceuticals, Inc. Announces Publication of Early Clinical Data of Olutasidenib in the Lancet Haematology

Third quarter 2022 earnings: EPS exceeds analyst expectations